Materias dentro de su búsqueda.
Mostrando 1,961 - 1,980 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.56s Limitar resultados
  1. 1961
    “…The human epidermal growth factor receptor 2 (HER2) is a well-established oncogenic driver and a successful therapeutic target in several malignancies, such as breast and gastric cancers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
  2. 1962
    “…ERBB2/HER2 is a novel susceptibility locus which contributes to cancer risk in combination with additional risk alleles. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Germline ERBB2/HER2 Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms
  3. 1963
    “…To meet the challenge, we developed polymer PLGA nanoparticles loaded with fluorescent photosensitive xanthene dye, Rose Bengal, and decorated with HER2-recognizing artificial scaffold protein, affibody Z(HER2:342). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    PLGA Nanoparticles Decorated with Anti-HER2 Affibody for Targeted Delivery and Photoinduced Cell Death
  4. 1964
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The sparkle in her eye: Crystal deposits in cornea, conjunctiva, meibombian glands, and iris in uncontrolled cystinosis
  5. 1965
    “…In a retrospective, observational study, we evaluated 73 patients from three centers in the United States and Canada with advanced HER2+ breast cancer that received at least one dose of T‐DM1. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Systemic toxicities of trastuzumab‐emtansine predict tumor response in HER2+ metastatic breast cancer
  6. 1966
    “…An alternative approach is to induce a polyclonal anti-EGFR/HER2 tumor antigen response by vaccine therapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer
  7. 1967
    “…SIMPLE SUMMARY: Tumor-infiltrating lymphocytes (TILs) are likely to play a role in the biological behavior of HER2+ ductal carcinoma in situ (DCIS). To prevent invasiveness, the potential of targeted immune-modulating treatment of HER2+ DCIS has been explored. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells
  8. 1968
    “…The influence of BC molecular subtype and gene expression on breast cancer brain metastasis (BCBM) development and patient prognosis is undeniable and is, therefore, an important focus point in the attempt to combat the disease. The HER2-positive and triple-negative molecular subtypes are associated with an increased risk of developing BCBM. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Molecular Mechanisms Associated with Brain Metastases in HER2-Positive and Triple Negative Breast Cancers
  9. 1969
    “…We aimed to compare disease characteristics and outcomes between HER2-low and HER2-0 in estrogen receptor (ER) positive, early-stage breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer
  10. 1970
    “…BACKGROUND: HER2 (ERBB2) activating mutations are present in 2–3% of lung adenocarcinomas; however, no targeted therapy is approved for HER2-altered lung cancers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study
  11. 1971
    “…The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis
  12. 1972
    “…HER2 testing should therefore be molecular subtype‐directed. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Performance of a HER2 testing algorithm specific for p53‐abnormal endometrial cancer
  13. 1973
    “…Over the last 20 years, treatment of patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer has considerably improved. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
  14. 1974
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer
  15. 1975
    “…The overexpression of tyrosine kinase HER2 in numerous cancers, connected with fierce signaling and uncontrolled proliferation, makes it a suitable target for immunotherapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Tetravalent Biparatopic Antibody Causes Strong HER2 Internalization and Inhibits Cellular Proliferation
  16. 1976
    “…Notably, HER2 CAR-T cells displayed greater aggressiveness in HER2(+) CRC in the patient-derived tumor xenograft (PDX) models and had potent immunotherapeutic capacity for mCRC in the metastatic xenograft mouse models. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer
  17. 1977
    “…BACKGROUND: Human epidermal growth factor receptor 2 (HER2) overexpressing malignancies, including breast and gastro-esophageal, are associated with a poor prognosis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis
  18. 1978
    “…Results: A “seesaw” relationship between ER/PR and Her2 pathways was observed in ER–PR–Her2 space, characterized by the expression levels of these 3 proteins. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    3D Visualization of the Dynamic Bidirectional Talk Between ER/PR and Her2 Pathways
  19. 1979
    “…Unlike patients with breast cancer, NSCLC patients can harbor either HER2-activating mutations or HER2 amplification coupled with protein overexpression. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy
  20. 1980
    “…The most prevalent breast cancer biomarker is the human epidermal growth factor receptor2 (HER2). As this biomarker is overexpressed in malignant breast tissues, it has become the main focus in targeted therapies to fight breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Quantum Dots: Synthesis, Antibody Conjugation, and HER2-Receptor Targeting for Breast Cancer Therapy
Herramientas de búsqueda: RSS